Skip to main content
SpringerLink
Log in

Antithrombotic therapy in cardiac stent patients

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

The use of coronary stents has made a significant impact on immediate angiographic results of coronary angioplasty as well as on the more important incidence of restenosis and the need for repeat procedures. This could not have been accomplished without adjuvant antithrombotic therapy directed predominantly at platelet function. Antiplatelet agents have significantly reduced the complications and improved the long-term outcome following coronary stent placement. This paper reviews the evolution of adjuvant antithrombotic therapy following stent placement, the agents currently used and future directions being investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Topol EJ, Mark DB, Lincoff AM, et al.: Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Lancet 1999, 354:2019–2024. One-year follow-up of the largest randomized trial of coronary stent implantation evaluating the concomitant use of abciximab therapy. The abciximab arm had a lower overall mortality and in diabetics the incidence of target vessel revascularization was less.

    Article  PubMed  CAS  Google Scholar 

  2. Serruys PW, deJacgere P, Kiemeneij F, et al.: for the Benestent Study Group: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994, 331:489–495.

    Article  PubMed  CAS  Google Scholar 

  3. Fischman DL, Leon MB, Baim DS, et al.: for the Stent Restenosis Study Investigators: A randomized comparison of coronarystent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994, 331:496–501.

    Article  PubMed  CAS  Google Scholar 

  4. Sigwart U, Puel J, Mirkovitch V, et al.: Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987, 316:701–706.

    Article  PubMed  CAS  Google Scholar 

  5. Hasdai D, Garratt KN, Holmes Jr. DR, et al.: Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. J Am Coll Cardiol 1996, 28:361–367.

    Article  PubMed  CAS  Google Scholar 

  6. Jeong MH, Owen WG, Staab ME, et al.: Porcine model of stent thrombosis: platelets are the primary component of acute stent closure. Cathet Cardiovasc Diagn 1996, 38:38–43.

    Article  PubMed  CAS  Google Scholar 

  7. Colombo A, Hall P, Nakamura S, et al.: Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995, 91:1676–1688.

    PubMed  CAS  Google Scholar 

  8. Schomig A, Neumann FJ, Kastrati A, et al.: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stent. N Engl J Med 1996, 334:1084–1089.

    Article  PubMed  CAS  Google Scholar 

  9. Leon MB, Baim DS, Popma JJ, et al.: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998, 339:1665–1671.

    Article  PubMed  CAS  Google Scholar 

  10. Bertrand ME, Legrand V, Boland J, et al.: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998, 98:1597–1603.

    PubMed  CAS  Google Scholar 

  11. Berger PB, Bell MR, Hasdai D, et al.: Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. Circulation 1999, 99:248–253.

    PubMed  CAS  Google Scholar 

  12. Quinn MJ, Fitzgerald DJ: Ticlopidine and clopidogrel. Circulation 1999, 100:1667–1672. Excellent review of these two antiplatelet agents and their role in coronary artery stent placement as well as peripheral vascular disease, unstable angina, and cerebrovascular disease.

    PubMed  CAS  Google Scholar 

  13. Bennett CL, Connors JM, Carwile JM, et al.: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000, 342:1773–1777.

    Article  PubMed  CAS  Google Scholar 

  14. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al.: Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998, 128:541–544.

    PubMed  CAS  Google Scholar 

  15. CAPRIE Steering Committee: A randomized, blinded trial of clopidrogel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996, 348:1329–1339.

    Article  Google Scholar 

  16. Berger PB, Bell MR, Rihal CS, et al.: Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999, 34:1891–1894.

    Article  PubMed  CAS  Google Scholar 

  17. Moussa I, Oetgen M, Roubin G, et al.: Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999, 99:2364–2366.

    PubMed  CAS  Google Scholar 

  18. Muller C, Buttner HJ, Petersen, Jens RH: A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000, 101:590–593.

    PubMed  CAS  Google Scholar 

  19. Ferguson JJ: Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology. Circulation 1999, 100:570–575.

    PubMed  CAS  Google Scholar 

  20. Waksman R, Bhargava B, Mintz GS, et al.: Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J Am Coll Cardiol 2000, 36:65–68.

    Article  PubMed  CAS  Google Scholar 

  21. Holmes Jr. DR: Platelet glycoprotein receptor site blockade in coronary artery disease. Curr Cardiol Rep 2000, 2:69–73.

    Article  PubMed  Google Scholar 

  22. Lincoff AM, Califf RM, Topol EJ: Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000, 35:1103–1115. Detailed summary of all the recent glycoprotein IIb/IIIa antagonist trials.

    Article  PubMed  CAS  Google Scholar 

  23. EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994, 330:956–961.

    Article  Google Scholar 

  24. EPILOG Investigators: Platelet glycoprotein IIb/IIIa blockade with abciximab with low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997, 336:1689–1696.

    Article  Google Scholar 

  25. EPISTENT Investigators: Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998, 352:87–92.

    Article  Google Scholar 

  26. Schomig A, Kastrati A, Dirschinger J, et al.: for the Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators: Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000, 343:385–391.

    Article  PubMed  CAS  Google Scholar 

  27. The IMPACT-II Investigators: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II [see comments]. Lancet 1997, 349:1422–1428.

    Article  Google Scholar 

  28. Tcheng JE: High dose eptifibatide in elective coronary stenting. Results of the ESPRIT trial. Presented at the 49th Annual Scientific Meetings of the American College of Cardiolgy. Anaheim, CA: March 12–15, 2000.

  29. Ault K, Cannon CP, Mitchell J, et al.: Platelet activation in patients after an acute coronary: results from the TIMI 12 trial. J Am Coll Cardiol 1999, 33:634–639.

    Article  PubMed  CAS  Google Scholar 

  30. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al.: Pharmacodynamic efficiency, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter placebo-controlled, randomized trial. Circulation 1998, 98:1268–1278.

    PubMed  CAS  Google Scholar 

  31. O’Neill WW, Serruys P, Knudtson M, et al.: for the EXCITE Trial Investigators: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. N Engl J Med 2000, 342:1316–1324.

    Article  PubMed  CAS  Google Scholar 

  32. Cannon CP, McCabe CH, Wilcox RG, et al.: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000, 102:149–156.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Diseases, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, 97201, Portland, OR, USA

    Charles R. Cannan MBChB, FACC

Authors
  1. Charles R. Cannan MBChB, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cannan, C.R. Antithrombotic therapy in cardiac stent patients. Curr Cardiol Rep 3, 78–84 (2001). https://doi.org/10.1007/s11886-001-0014-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-001-0014-0

Keywords

Search

Navigation